By: Jay Silverman
The Medicines Co. (MDCO) had a highly successful 2015; in my view, the upcoming year will include updates on at least four future growth drivers and further execution of the strategic plan put in place towards the end of the year.
With the cardiovascular drug MDCO-216 about to gain visibility, now three potential blockbuster compounds including ‘216, ALN-PCS (cholesterol reduction), and ABP-7000 (surgical anesthetic) resulted in positive first-look (i.e., Phase I/II) clinical trials.
The best-in-class PCSK-9 inhibitor under development, ALN-PCS can significantly lower cholesterol levels and hold them down for six months.
Hence, the drug may be dosed only twice a year, way less than the 24x in the AMGN Repatha and REGN/SNY Praluent labels. ABP-7000 can become next propofol, the most widely short-term procedural anesthetic.